Clinical trials: Cytomegalovirus Viraemia
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Cytomegalovirus Infections
Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR
The overall purpose of this research is to develop and use a blood test to better understand how quickly the viral drug ganciclovir works to clear infection with the CMV virus (Cytomegalovirus) when it occurs.
- Trial name
- NCT00004573
- Testing
- ganciclovir
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
CMV Viremia
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation and commonly presents as an…
- Trial name
- CYPHER-TXPilot (NCT05432778)
- Testing
- Letermovir Pill
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- University Medical Centre Ljubljana
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cytomegalovirus Infections, Cytomegalovirus Viremia
HCMV Breakthrough Infections During Letermovir Prophylaxis
The goal of this clinical trial is to compare two strategies to monitor human cytomegalovirus (HCMV) infections in transplanted patients receiving letermovir (LTV) as anti-HCMV prophylaxis.
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- CMVbreak (NCT06339892)
- Testing
- Determination of HCMV DNA in plasma after DNAse digestion., Determination of HCMV DNA in blood or plasma.
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cytomegalovirus Infections
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
- Trial name
- NCT04478474
- Testing
- Ganciclovir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York Medical College
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Viraemia
CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and…
- Trial name
- NCT01883206
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Cytomegalovirus Viraemia
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis.
- Trial name
- Q-CMV (NCT02370758)
- Testing
- Valganciclovir or Ganciclovir
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
- Trial name
- NCT05089838
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xiao-Jun Huang
Hematologic Diseases, Stem Cell Transplant Complications
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
Prospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian with objective to describe the incidence of CMV infections and diseases in adult and pediatric patients undergoing…
- Conditions
- Hematologic Diseases, Stem Cell Transplant Complications, Cytomegalovirus Viremia, Herpesvirus Infection
- Trial name
- CYTOALLOSURVEY (NCT04412811)
- Where
- 50 sites in Italy
- Volunteers
- 1,310 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
CMV, AdV Infection
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
- Conditions
- CMV, AdV Infection, AdV Reactivation, Adenovirus
- Trial name
- NCT07225972
- Testing
- Standard of Care Antiviral medications, Viral CTLs
- Where
- 2 sites in United States
- Volunteers
- 138 people
- Sponsor
- New York Medical College
Acute Leukemia, CMV Viremia
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
- Conditions
- Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04298502
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Cytomegalovirus Viraemia
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ…
- Trial name
- QFT-CMV (NCT02784756)
- Testing
- Quantiferon-CMV assay
- Where
- 6 sites in Canada, Spain
- Volunteers
- 134 people
- Sponsor
- University Health Network, Toronto
SLE (Systemic Lupus), CMV
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.
- Trial name
- NCT06971913
- Testing
- Interleukin-2 (IL-2), Ganciclovir (GCV)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Cytomegalovirus Infections, CMV
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation.
- Conditions
- Cytomegalovirus Infections, CMV, Kidney Transplant Infection
- Trial name
- NCT03858907
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- University of Sao Paulo General Hospital
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing…
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT03560752
- Testing
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
CMV Infection, Cytomegalovirus Infections
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections…
- Conditions
- CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
- Trial name
- NCT03798301
- Testing
- CMV-specific T-cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Cytomegalovirus Infections, HIV Infections
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is…
- Trial name
- NCT00006145
- Testing
- Valganciclovir
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)